P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy

Human Pathology

Volumn 43, Issue 11, 2012, Pages 1948-1954

  Borys, Dariusz ^a   Canter, Robert J ^a   Hoch, Benjamin ^b   Martinez, Steve R ^a   Tamurian, Robert M ^c   Murphy, Brian ^d   Bishop, John W ^a   Horvai, Andrew ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Osteosarcoma; p16INK4a; Tumor necrosis

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P16;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL PROTOCOL; FEMALE; FEMUR TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PREDICTION; PROTEIN EXPRESSION; SCHOOL CHILD; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR NECROSIS;

EID: 84867855432     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.02.003     Document Type: Article

References (35)

1. S. Ferrari, S. Smeland, and M. Mercuri Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups J Clin Oncol 23 2005 8845 8852
2. G. Bacci, S. Ferrari, and A. Longhi High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study J Chemother 14 2002 198 206
3. G. Bacci, P. Picci, and S. Ferrari Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: the recent experience at the Rizzoli Institute Cancer Treat Res 62 1993 299 308
4. D.S. Geller, and R. Gorlick Osteosarcoma: a review of diagnosis, management, and treatment strategies Clin Adv Hematol Oncol 8 2010 705 718
5. G. Bacci, S. Ferrari, and A. Longhi Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol J Chemother 13 2001 93 99
6. G. Bacci, S. Ferrari, and F. Bertoni Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy Clin Orthop Relat Res 2001 186 196
7. G. Bacci, M. Mercuri, and A. Longhi Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution Eur J Cancer 41 2005 2079 2085
8. G. Bacci, F. Bertoni, and A. Longhi Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor Cancer 97 2003 3068 3075
9. A.J. Provisor, L.J. Ettinger, and J.B. Nachman Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group J Clin Oncol 15 1997 76 84
10. S. Smeland, C. Muller, and T.A. Alvegard Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders Eur J Cancer 39 2003 488 494
11. P.A. Meyers, R. Gorlick, and G. Heller Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol J Clin Oncol 16 1998 2452 2458
12. S. Zelcer, M. Kellick, and L.H. Wexler Methotrexate levels and outcome in osteosarcoma Pediatr Blood Cancer 44 2005 638 642
13. G. Bacci, C. Forni, and S. Ferrari Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome J Pediatr Hematol Oncol 25 2003 845 853
14. H.Z. Chen, S.Y. Tsai, and G. Leone Emerging roles of E2Fs in cancer: an exit from cell cycle control Nat Rev Cancer 9 2009 785 797
15. W. Du, and J.S. Searle The rb pathway and cancer therapeutics Curr Drug Targets 10 2009 581 589
16. M.S. Benassi, L. Molendini, and G. Gamberi Alteration of pRb/p16/cdk4 regulation in human osteosarcoma Int J Cancer 84 1999 489 493
17. A. Maitra, H. Roberts, A.G. Weinberg, and J. Geradts Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas Int J Cancer 95 2001 34 38
18. A.B. Mohseny, C. Tieken, and P.A. van der Velden Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma Genes Chromosomes Cancer 49 2010 1095 1103
19. A.G. Huvos Clinicopathologic spectrum of osteogenic sarcoma. Recent observations Pathol Annu 1 14 Pt 1979 123 144
20. A.G. Huvos Surgical pathology of bone sarcomas World J Surg 12 1988 284 298
21. S. Ferrari, F. Bertoni, and M. Mercuri Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute Ann Oncol 12 2001 1145 1150
22. S. Ferrari, M. Mercuri, and P. Picci Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response Tumori 85 1999 458 464
23. N. Baldini, K. Scotlandi, and G. Barbanti-Brodano Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome N Engl J Med 333 1995 1380 1385
24. N. Baldini, K. Scotlandi, and M. Serra P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy J Orthop Res 17 1999 629 632
25. M. Serra, K. Scotlandi, and G. Reverter-Branchat Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities J Clin Oncol 21 2003 536 542
26. R. Gorlick, A.C. Liao, and C. Antonescu Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma Clin Cancer Res 7 2001 3065 3070
27. R. Gorlick, A.G. Huvos, and G. Heller Expression of HER2/erbB-2 correlates with survival in osteosarcoma J Clin Oncol 17 1999 2781 2788
28. G.R. Somers, M. Ho, M. Zielenska, J.A. Squire, and P.S. Thorner HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study Pediatr Dev Pathol 8 2005 525 532
29. N.A. Hernandez-Rodriguez, E. Correa, and R. Sotelo Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma Cancer Detect Prev 25 2001 210 215
30. V.H. Bramwell, M.V. Burgers, and R.L. Souhami A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: a study of the European Osteosarcoma Intergroup Sarcoma 1 1997 155 160
31. R.L. Souhami, A.W. Craft, and J.W. Van der Eijken Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup Lancet 350 1997 911 917
32. M. Merli, M.S. Benassi, and G. Gamberi Expression of G1 phase regulators in MG-63 osteosarcoma cell line Int J Oncol 14 1999 1117 1121
33. L. Molendini, M.S. Benassi, and G. Magagnoli Prognostic significance of cyclin expression in human osteosarcoma Int J Oncol 12 1998 1007 1011
34. T. Tsuchiya, K. Sekine, S. Hinohara, T. Namiki, T. Nobori, and Y. Kaneko Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma Cancer Genet Cytogenet 120 2000 91 98
35. M.S. Benassi, L. Molendini, and G. Gamberi Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma Cancer 92 2001 3062 3067